27601594|t|Neoadjuvant Chemotherapy of Ovarian Cancer Results in Three Patterns of Tumor-Infiltrating Lymphocyte Response with Distinct Implications for Immunotherapy
27601594|a|Purpose: Some forms of chemotherapy can enhance antitumor immunity through immunogenic cell death, resulting in increased T-cell activation and tumor infiltration. Such effects could potentially sensitize tumors to immunotherapies, including checkpoint blockade. We investigated whether platinum - and taxane -based chemotherapy for ovarian cancer induces immunologic changes consistent with this possibility. Experimental Design: Matched pre - and post - neoadjuvant chemotherapy tumor samples from 26 high-grade serous carcinoma (HGSC) patients were analyzed by immunohistochemistry (IHC) for a large panel of immune cells and associated factors. The prognostic significance of post - chemotherapy TIL patterns was assessed in an expanded cohort (n = 90).Results: Neoadjuvant chemotherapy was associated with increased densities of CD3 (+), CD8 (+), CD8 (+) TIA-1 (+), PD-1 (+) and CD20 (+) TIL. Other immune subsets and factors were unchanged, including CD79a (+) CD138 (+) plasma cells, CD68 (+) macrophages, and MHC class I on tumor cells. Immunosuppressive cell types were also unchanged, including FoxP3 (+) PD-1 (+) cells (putative regulatory T cells), IDO-1 (+) cells, and PD-L1 (+) cells (both macrophages and tumor cells). Hierarchical clustering revealed three response patterns: (i) TIL (high) tumors showed increases in multiple immune markers after chemotherapy; (ii) TIL (low) tumors underwent similar increases, achieving patterns indistinguishable from the first group; and (iii) TIL (negative) cases generally remained negative. Despite the dramatic increases seen in the first two patterns, post- chemotherapy TIL showed limited prognostic significance.Conclusions: Chemotherapy augments pre-existing TIL responses but fails to relieve major immune-suppressive mechanisms or confer significant prognostic benefit. Our findings provide rationale for multipronged approaches to immunotherapy tailored to the baseline features of the tumor microenvironment. Clin Cancer Res; 23(4); 925-34. Â©2016 AACR.
27601594	0	24	Neoadjuvant Chemotherapy	T061	C4272610
27601594	28	42	Ovarian Cancer	T191	C0029925
27601594	72	101	Tumor-Infiltrating Lymphocyte	T025	C0079722
27601594	102	110	Response	T039	C0301909
27601594	142	155	Immunotherapy	T061	C0278348
27601594	179	191	chemotherapy	T061	C0392920
27601594	204	213	antitumor	T080	C2986475
27601594	214	222	immunity	T039	C0020964
27601594	231	242	immunogenic	T169	C0872192
27601594	243	253	cell death	T043	C0007587
27601594	278	295	T-cell activation	T043	C1155065
27601594	300	318	tumor infiltration	T191	C4060690
27601594	361	367	tumors	T191	C0027651
27601594	371	386	immunotherapies	T061	C0278348
27601594	398	417	checkpoint blockade	T043	C1155873
27601594	443	451	platinum	T196	C0032207
27601594	458	464	taxane	T109,T121	C0215136
27601594	472	484	chemotherapy	T061	C0392920
27601594	489	503	ovarian cancer	T191	C0029925
27601594	512	523	immunologic	T169	C0205470
27601594	566	585	Experimental Design	T062	C0015320
27601594	595	598	pre	T079	C0332152
27601594	605	609	post	T079	C0687676
27601594	612	636	neoadjuvant chemotherapy	T061	C4272610
27601594	637	650	tumor samples	T024	C0475358
27601594	659	686	high-grade serous carcinoma	T191	C3839280
27601594	688	692	HGSC	T191	C3839280
27601594	720	740	immunohistochemistry	T060	C0021044
27601594	742	745	IHC	T060	C0021044
27601594	768	780	immune cells	T025	C0312740
27601594	836	840	post	T079	C0687676
27601594	843	855	chemotherapy	T061	C0392920
27601594	856	859	TIL	T025	C0079722
27601594	897	903	cohort	T098	C0599755
27601594	922	946	Neoadjuvant chemotherapy	T061	C4272610
27601594	990	993	CD3	T116,T129	C0108779
27601594	999	1002	CD8	T129	C0085358
27601594	1008	1011	CD8	T129	C0085358
27601594	1016	1021	TIA-1	T116,T129	C1429678
27601594	1027	1031	PD-1	T116,T129,T192	C2986635
27601594	1040	1044	CD20	T116,T129	C0054946
27601594	1049	1052	TIL	T025	C0079722
27601594	1113	1118	CD79a	T116,T192	C0286618
27601594	1123	1128	CD138	T116,T123	C1609943
27601594	1133	1145	plasma cells	T025	C0032112
27601594	1147	1151	CD68	T116,T129	C0108799
27601594	1156	1167	macrophages	T025	C0024432
27601594	1173	1184	MHC class I	T116,T129	C0019629
27601594	1188	1199	tumor cells	T025	C0597032
27601594	1201	1218	Immunosuppressive	T047	C4048329
27601594	1219	1223	cell	T025	C0007634
27601594	1261	1266	FoxP3	T116,T123	C4282118
27601594	1271	1275	PD-1	T116,T129,T192	C2986635
27601594	1280	1285	cells	T025	C0039198
27601594	1296	1314	regulatory T cells	T025	C0039198
27601594	1317	1322	IDO-1	T116,T126	C3529891
27601594	1338	1343	PD-L1	T129	C4300350
27601594	1360	1371	macrophages	T025	C0024432
27601594	1376	1387	tumor cells	T025	C0597032
27601594	1390	1413	Hierarchical clustering	T062	C1881045
27601594	1452	1455	TIL	T025	C0079722
27601594	1463	1469	tumors	T191	C0027651
27601594	1499	1513	immune markers	T080	C0162489
27601594	1520	1532	chemotherapy	T061	C4272610
27601594	1539	1542	TIL	T025	C0079722
27601594	1654	1657	TIL	T025	C0079722
27601594	1659	1667	negative	T033	C0205160
27601594	1694	1702	negative	T033	C0205160
27601594	1773	1785	chemotherapy	T061	C0392920
27601594	1786	1789	TIL	T025	C0079722
27601594	1842	1854	Chemotherapy	T061	C4272610
27601594	1877	1880	TIL	T025	C0079722
27601594	1881	1890	responses	T039	C0301909
27601594	1918	1947	immune-suppressive mechanisms	T047	C1840264
27601594	2052	2065	immunotherapy	T061	C0278348
27601594	2107	2129	tumor microenvironment	T070	C2936626